Johnson & Johnson: Rybrevant Faspro Plus Lazcluze With Prophylactic Strategies Shows Low Rates of Treatment-related Events at WCLC 2026
September 16, 2026
September 16, 2026
RARITAN, New Jersey, Sept. 16 -- Johnson and Johnson Innovative Medicine issued the following news release:
* * *
RYBREVANT FASPRO(TM) (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE(R) (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
Low rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxis
Fewer than 1% of patients disconti . . .
* * *
RYBREVANT FASPRO(TM) (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE(R) (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
Low rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxis
Fewer than 1% of patients disconti . . .